Volume 31, Issue 3 (10-2007)
Research in Medicine 2007, 31(3): 297-289 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sharifi R, Hedayati M, Rasmi Y, Rahmati-Yamchi M, Fatemi F, Dadkhah A et al . Cyclooxygenase prevention and treatment. Research in Medicine 2007; 31 (3) :297-289
URL: http://pejouhesh.sbmu.ac.ir/article-1-422-en.html
URL: http://pejouhesh.sbmu.ac.ir/article-1-422-en.html
, allameha@modares.ac.ir
Abstract: (18010 Views)
Cyclooxygenase (COX) is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two cycloxygenase isoforms have been identified and are referred to as COX-1 and COX-2. Both enzymes are blocked by nonselective anti-inflammatory drugs (NSAID), such as indomethacin and ibuprofen. COX-1 is an enzyme normally found in tissues and is involved in physiological functions, while COX-2 is an acute phase reactant associated with inflammation. Recently, COX-2 has been found to be associated with hyperalgesia, angiogenesis, cancer and Alzheimerُs disease. The suggestion that COX-2 is causally linked to cancer offers a new approach to extending our knowledge about the neoplastic phenomenon and improving management of human malignant diseases.
Type of Study: Review |
Received: 2008/04/19 | Published: 2007/10/15
Received: 2008/04/19 | Published: 2007/10/15
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This Journal is licensed under a Creative Commons Attribution 4.0 International License | Research in Medicine
Designed & Developed by : Yektaweb